Hosted on MSN

First-in-class KRAS-degrader promising in pancreatic, lung cancers

Setidegrasib showed promising efficacy in patients with previously treated advanced KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC), results from a ...
MedPage Today on MSN

Novel KRAS Drug Shows 'Excellent' Efficacy in Tough-to-Treat Lung Cancer

Zoldonrasib ideal for further evaluation in KRAS G12D-mutant disease, expert says ...
Morningstar

PAQ Therapeutics Announces Series B Extension, Bringing Total Series B Financing to $77 Million; First Patient Dosed in Phase 1 Trial of PT0511, a Pan-KRAS Degrader

BURLINGTON, Mass., Jan. 22, 2026 /PRNewswire/ -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced ...
Seeking Alpha

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ARV‑806 is a novel, investigational PROTAC degrader designed to selectively target and degrade mutant Kirsten rat sarcoma (KRAS) G12D. KRAS is one of the most frequently mutated human oncogenes and ...
Fred Hutch

Tricking cells into trashing cancer

Many cancer drugs work by inhibiting the activity of proteins — the molecules that do most of the work in the cell. But some misbehaving proteins that turn normal cells cancerous are difficult to ...
The New England Journal of Medicine

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...